Chikungunya cases are rising in French Guiana, with health authorities reporting a steady increase since January 2026. The virus, transmitted by daytime-biting mosquitoes including the Aedes albopictus species commonly known as tiger mosquitoes, has prompted renewed public health action. According to Santé publique France, 81 confirmed cases were recorded by April 9, 2026, with the western part of the territory most affected.
In response to the resurgence, the French High Authority for Health (HAS) issued a vaccine recommendation on April 14, 2026, following a request from the Ministry of Health on February 25, 2026. The guidance supports the utilize of two authorized vaccines—Vimkunya by Bavarian Nordic and Ixchiq by Valneva—for populations at higher risk of severe disease. This marks the first time these vaccines, previously approved only for travelers in Europe, are being recommended for general use in an outbreak setting within French overseas territories.
The HAS specifically advises Vimkunya for individuals aged 65 and older, as well as those between 12 and 64 years old with underlying health conditions that increase vulnerability to severe chikungunya infection. For the broader population aged 12 to 64 without comorbidities, either vaccine may be considered based on clinical judgment and availability. The agency emphasized that vaccination remains voluntary and requires a medical prescription.
Regional health officials confirmed that vaccine doses would be distributed starting the week of April 20, 2026, and would be provided free of charge through the Guyanese Regional Health Agency (ARS). Bertrand Parent, director of ARS Guyane, stated that the region was recording approximately ten recent cases per week at the time of the announcement, bringing the cumulative total to 102 cases by mid-April.
Health experts note that despite the current circulation, population immunity remains low a decade after the last major epidemic, leaving communities susceptible to further spread. Severe outcomes are more likely in extreme age groups and those with comorbidities such as diabetes, cardiovascular disease, or immunosuppression. Whereas most infections cause acute fever and joint pain, a subset can lead to prolonged arthralgia lasting months or even years.
The vaccines perform by stimulating an immune response against the chikungunya virus. Vimkunya is a live attenuated vaccine requiring a single dose, while Ixchiq is also a single-dose live attenuated vaccine but differs in its viral strain and production method. Both have demonstrated efficacy in clinical trials, with real-world data now being collected during the Guyane outbreak to assess effectiveness and safety in endemic conditions.
Public health teams are coordinating with local clinics and community leaders to raise awareness about mosquito bite prevention alongside vaccination efforts. Recommended protective measures include using insect repellent, wearing long sleeves, and eliminating standing water where mosquitoes breed. The ARS Guyane has launched targeted outreach in the western communes where transmission is most intense.
As of mid-April 2026, no deaths have been officially attributed to the current chikungunya wave in French Guiana. Health authorities continue to monitor hospitalization rates and neurological complications, which, though rare, have been documented in previous outbreaks. The situation remains under active surveillance, with weekly updates expected from Santé publique France.
Looking ahead, the next official update on case numbers and vaccination progress is anticipated from the ARS Guyane by late April 2026. The HAS may refine its guidance based on accumulating data from the field, including vaccine uptake and any observed adverse events. For now, the focus remains on protecting the most vulnerable while expanding access to prevention tools across the territory.
Stay informed through official channels such as the French Ministry of Health and Santé publique France for the latest developments on chikungunya in Guyane. Share this article to help spread accurate information about prevention and vaccination options.